Many factors influence firms’ growth possibilities and market positions. This paper deals with business models as company’s competitiveness determinant; the case of Russian leading pharmaceutical companies is studied. The review of global pharmaceutical leaders’ business models is presented. Russian leaders are indentified basing on empirical data provided by SPARK database. It has been found that they use models of disruptive research, models aimed at business value growth as well as models of active portfolio management. Characteristics and perspectives of each model type are determined.